Shared Decision Making for Antipsychotic Medications

NANot yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
SchizophreniaSchizoaffective DisorderSchizophreniform DisordersDelusional DisorderOther Specified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
OTHER

The Antipsychotic Medication Decision Aid (APM-DA)

The APM-DA intervention is the first and only International Patient Decision Aid Standards (IPDAS) approved shared decision making (SDM) decision aid intervention for Antipsychotic Medication decisions in psychiatric visits. The APM-DA intervention developed by the research team addresses a common issue among psychiatric care providers and patients that lies in the heart of pharmacotherapy - taking, tapering or stopping APM. The APM-DA has a print format and can be used online as a PDF. It includes a concise table describing what each option involves, its benefits, risks, and strategies to reduce risks. The intervention was developed in co-production with various stakeholders (patients, clinicians, service leadership, family members, researchers). Additional intervention materials are an evidence document to support the information and an APM side effects table.

All Listed Sponsors
collaborator

Temple University

OTHER

lead

New York State Psychiatric Institute

OTHER

NCT05416658 - Shared Decision Making for Antipsychotic Medications | Biotech Hunter | Biotech Hunter